OA
VIR icon

Oracle Alpha’s Vir Biotechnology VIR Stock Holding History

Oracle Alpha’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$207K Buy
20,430
+1,368
+7% +$13.9K 0.37% 139
2023
Q4 		$192K Buy
+19,062
New +$174K 0.25% 193

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GF
Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Oracle Alpha's VIR Position: Q1 2024 in Review

Oracle Alpha increased its Vir Biotechnology (VIR) stake by 7.2% in Q1 2024, buying an estimated $13.9K and bringing the position to 20,430 shares worth $207K. The position accounts for 0.37% of the portfolio, ranked #139.

Oracle Alpha first reported a position in VIR in Q4 2023 and has held it in 2 quarters since. 209 funds tracked by Wall St. Rank hold VIR as of Q1 2024.

  • Oracle Alpha held 20,430 shares of Vir Biotechnology worth $207K as of Q1 2024.
  • Oracle Alpha bought 1,368 Vir Biotechnology shares in Q1 2024, an estimated $13.9K.
  • Vir Biotechnology made up 0.37% of Oracle Alpha's portfolio in Q1 2024, its #139 holding.
  • Oracle Alpha first reported a position in Vir Biotechnology in Q4 2023 and has held it in 2 quarters since.
  • 209 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2024.

Based on Oracle Alpha's 13F filing for Q1 2024, filed 15 May 2024.